Investigational Cushing’s syndrome medication reduces BP, glucose in open-label trial
Adults with endogenous Cushing’s syndrome had reductions in blood pressure and glucose at 22 weeks of treatment with a selective cortisol modulator, according to topline results from the open-label ...
